< 1 minute read
Sep. 17, 2021

BMS-986251: A Selective RORgt Inverse Agonist

BMS-986251

selective RORgt inverse agonist entered clinical dev. (psoriasis), discontinued from HTS and SBDD ACS Med. Chem. Lett., Apr. 10, 2020 Bristol Myers Squibb, Princeton, NJ

twitterlinkedinprintemail